Skip to content

Study · Animal study (in vivo) · rat · 2015

4 results

Exendin-4, a glucagon-like peptide-1 receptor agonist, reduces Alzheimer disease-associated tau hyperphosphorylation in the hippocampus of rats with type 2 diabetes.

Xu W, Yang Y, Yuan G, Zhu W, Ma D, Hu S

Journal of investigative medicine : the official publication of the American Federation for Clinical Research1 Feb 2015Cited by 76 (Europe PMC)

PMID25479064 (opens in a new tab)DOI10.1097/jim.0000000000000129 (opens in a new tab)PepBankPUB-25479064
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In T2D rats, exendin‑4 decreased hippocampal tau phosphorylation at Ser199/202.

    In plain wordsIn rats with diabetes, exendin‑4 reduced hippocampal tau phosphorylation at Ser199/202.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTau Ser199/202 phosphorylation
    Study

    ratn: not reported in source

    type 2 diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · injection · 28 consecutive daysAs given in this study (rat).

    Source sentences

    Summary
    The levels of phosphorylated tau protein at site Ser199/202 and Thr217 level in the hippocampus of T2D rats were found to be raised notably and evidently decreased after EX-4 intervention.
    1 context sentence
    Summary · context
    Type 2 diabetes rats were injected with EX-4 for 28 consecutive days.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In T2D rats, exendin‑4 decreased hippocampal tau phosphorylation at Thr217.

    In plain wordsIn rats with diabetes, exendin‑4 reduced hippocampal tau phosphorylation at Thr217.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseTau Thr217 phosphorylation
    Study

    ratn: not reported in source

    type 2 diabetes
    Outcome group
    Neuroprotection · Nervous system and cognition
    Studied dose
    Dose not stated · injection · 28 consecutive daysAs given in this study (rat).

    Source sentences

    Summary
    The levels of phosphorylated tau protein at site Ser199/202 and Thr217 level in the hippocampus of T2D rats were found to be raised notably and evidently decreased after EX-4 intervention.
    1 context sentence
    Summary · context
    Type 2 diabetes rats were injected with EX-4 for 28 consecutive days.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In T2D rats, exendin‑4 increased hippocampal PI3K/AKT activity after intervention.

    In plain wordsIn rats with diabetes, exendin‑4 increased hippocampal PI3K/AKT activity.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreasePI3K/AKT activity
    Study

    ratn: not reported in source

    type 2 diabetes
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · injection · 28 consecutive daysAs given in this study (rat).

    Source sentences

    Summary
    a rise in PI3K/AKT activity and a decline in GSK-3β activity after 4 weeks intervention of EX-4.
    1 context sentence
    Summary · context
    Type 2 diabetes rats were injected with EX-4 for 28 consecutive days.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In T2D rats, exendin‑4 decreased hippocampal GSK-3β activity after intervention.

    In plain wordsIn rats with diabetes, exendin‑4 decreased hippocampal GSK-3β activity.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseGSK-3β activity
    Study

    ratn: not reported in source

    type 2 diabetes
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    Dose not stated · injection · 28 consecutive daysAs given in this study (rat).

    Source sentences

    Summary
    a rise in PI3K/AKT activity and a decline in GSK-3β activity after 4 weeks intervention of EX-4.
    1 context sentence
    Summary · context
    Type 2 diabetes rats were injected with EX-4 for 28 consecutive days.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.